- Home
- AHT vs MRSN Comparison
AHT vs MRSN Comparison
Compare AHT & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHT
- MRSN
- Stock Information
- Founded
- AHT 2003
- MRSN 2001
- Country
- AHT United States
- MRSN United States
- Employees
- AHT 116
- MRSN N/A
- Industry
- AHT Real Estate Investment Trusts
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AHT Real Estate
- MRSN Health Care
- Exchange
- AHT Nasdaq
- MRSN Nasdaq
- Market Cap
- AHT 34.3M
- MRSN 40.7M
- IPO Year
- AHT 2003
- MRSN 2017
- Fundamental
- Price
- AHT $6.15
- MRSN $0.33
- Analyst Decision
- AHT
- MRSN Strong Buy
- Analyst Count
- AHT 0
- MRSN 5
- Target Price
- AHT N/A
- MRSN $5.75
- AVG Volume (30 Days)
- AHT 44.2K
- MRSN 2.0M
- Earning Date
- AHT 07-29-2025
- MRSN 08-12-2025
- Dividend Yield
- AHT N/A
- MRSN N/A
- EPS Growth
- AHT N/A
- MRSN N/A
- EPS
- AHT N/A
- MRSN N/A
- Revenue
- AHT $1,143,655,000.00
- MRSN $34,006,000.00
- Revenue This Year
- AHT N/A
- MRSN N/A
- Revenue Next Year
- AHT N/A
- MRSN $1.30
- P/E Ratio
- AHT N/A
- MRSN N/A
- Revenue Growth
- AHT N/A
- MRSN N/A
- 52 Week Low
- AHT $5.20
- MRSN $0.26
- 52 Week High
- AHT $11.99
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- AHT 54.79
- MRSN 41.92
- Support Level
- AHT $5.50
- MRSN $0.33
- Resistance Level
- AHT $6.33
- MRSN $0.37
- Average True Range (ATR)
- AHT 0.52
- MRSN 0.03
- MACD
- AHT 0.04
- MRSN -0.00
- Stochastic Oscillator
- AHT 56.52
- MRSN 1.24
About AHT Ashford Hospitality Trust Inc
Ashford Hospitality Trust Inc. is a real estate investment trust that invests in full-service upscale and upper-upscale hotel properties in the U.S. The company owns and operates its assets through its operating partnership, Ashford Hospitality Limited Partnership. All of its hotels are located across the U.S. and operate under the Marriott, Hilton, Hyatt, Crowne Plaza, and Sheraton brands. Ashford's sole segment is Direct Hotel Investments, through which it owns hotels by acquisition or development. Ashford also provides real estate investment services, such as mezzanine financing, first mortgage financing, and sales-leaseback transactions. Its revenue streams include Room revenue, Food and beverage revenue, and Other revenue. Room revenue accounts for the majority of total revenue.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.